A case of late onset myoclonic epilepsy in Down syndrome (LOMEDS)

Research output: Contribution to journalArticle

Abstract

Myoclonic epilepsy is being increasingly recognized as a late onset complication in middle-aged or elderly patients with Down syndrome, in association with acute cognitive decline or dementia. We report a case of late onset myoclonic epilepsy in Down syndrome (LOMEDS) with acute cognitive decline, aged 45 year-olds. Although her intelligence condition remained poor with one to two-words sentences and difficult in following commands even after treatment, induction of levetiracetam and lamotorigin resulted in rapid, sustained seizure freedom and upgrading social activity with no adverse events. A combination of levetiracetam and lamotorigin appear to be effective for LOMEDS, and could be considered as first line agents for this special condition.

Original languageEnglish
Pages (from-to)564-567
Number of pages4
JournalJournal of the Japan Epilepsy Society
Volume32
Issue number3
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

etiracetam
Myoclonic Epilepsy
Down Syndrome
Intelligence
Dementia
Seizures
Cognitive Dysfunction
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

A case of late onset myoclonic epilepsy in Down syndrome (LOMEDS). / Ishibashi, Hideaki; Shigeto, Hiroshi; Onitsuka, Toshiaki.

In: Journal of the Japan Epilepsy Society, Vol. 32, No. 3, 01.01.2015, p. 564-567.

Research output: Contribution to journalArticle

@article{749f61607e414c13aa3034a367565b3a,
title = "A case of late onset myoclonic epilepsy in Down syndrome (LOMEDS)",
abstract = "Myoclonic epilepsy is being increasingly recognized as a late onset complication in middle-aged or elderly patients with Down syndrome, in association with acute cognitive decline or dementia. We report a case of late onset myoclonic epilepsy in Down syndrome (LOMEDS) with acute cognitive decline, aged 45 year-olds. Although her intelligence condition remained poor with one to two-words sentences and difficult in following commands even after treatment, induction of levetiracetam and lamotorigin resulted in rapid, sustained seizure freedom and upgrading social activity with no adverse events. A combination of levetiracetam and lamotorigin appear to be effective for LOMEDS, and could be considered as first line agents for this special condition.",
author = "Hideaki Ishibashi and Hiroshi Shigeto and Toshiaki Onitsuka",
year = "2015",
month = "1",
day = "1",
doi = "10.3805/jjes.32.564",
language = "English",
volume = "32",
pages = "564--567",
journal = "Journal of the Japan Epilepsy Society",
issn = "0912-0890",
publisher = "Japan Epilepsy Society",
number = "3",

}

TY - JOUR

T1 - A case of late onset myoclonic epilepsy in Down syndrome (LOMEDS)

AU - Ishibashi, Hideaki

AU - Shigeto, Hiroshi

AU - Onitsuka, Toshiaki

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Myoclonic epilepsy is being increasingly recognized as a late onset complication in middle-aged or elderly patients with Down syndrome, in association with acute cognitive decline or dementia. We report a case of late onset myoclonic epilepsy in Down syndrome (LOMEDS) with acute cognitive decline, aged 45 year-olds. Although her intelligence condition remained poor with one to two-words sentences and difficult in following commands even after treatment, induction of levetiracetam and lamotorigin resulted in rapid, sustained seizure freedom and upgrading social activity with no adverse events. A combination of levetiracetam and lamotorigin appear to be effective for LOMEDS, and could be considered as first line agents for this special condition.

AB - Myoclonic epilepsy is being increasingly recognized as a late onset complication in middle-aged or elderly patients with Down syndrome, in association with acute cognitive decline or dementia. We report a case of late onset myoclonic epilepsy in Down syndrome (LOMEDS) with acute cognitive decline, aged 45 year-olds. Although her intelligence condition remained poor with one to two-words sentences and difficult in following commands even after treatment, induction of levetiracetam and lamotorigin resulted in rapid, sustained seizure freedom and upgrading social activity with no adverse events. A combination of levetiracetam and lamotorigin appear to be effective for LOMEDS, and could be considered as first line agents for this special condition.

UR - http://www.scopus.com/inward/record.url?scp=84925442101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925442101&partnerID=8YFLogxK

U2 - 10.3805/jjes.32.564

DO - 10.3805/jjes.32.564

M3 - Article

VL - 32

SP - 564

EP - 567

JO - Journal of the Japan Epilepsy Society

JF - Journal of the Japan Epilepsy Society

SN - 0912-0890

IS - 3

ER -